Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/23 10:00:51 pm
118.81 USD   -0.54%
09/25 JOHNSON & JOHNS : The Philadelphia Inquirer Kellie Patrick Gates col..
09/24 PFIZER INC. : vs. Johnson & Johnson
09/23 JOHNSON & JOHNS : Michael Ullmann Appointed to Princeton Area Commun..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2012 | 05:50pm CEST

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
09/25 JOHNSON & JOHNSON : The Philadelphia Inquirer Kellie Patrick Gates column
09/25 JOHNSON & JOHNSON : Dennis W. Weaver
09/24 PFIZER INC. : vs. Johnson & Johnson
09/23 JOHNSON & JOHNSON : Michael Ullmann Appointed to Princeton Area Community Founda..
09/23 JOHNSON & JOHNSON : Parametric Portfolio Associates buys $772,134,349 stake in J..
09/22 JOHNSON & JOHNSON : U.S. FDA Approves INVOKAMET® XR (Canagliflozin / Metformin H..
09/21 GLOBAL BABY BATH PRODUCT MARKET 2016 : Mamas and Papas, Johnson and Johnson, Fis..
09/21 GLOBAL BABY OIL MARKET 2016 : Pigeon, Chicco, Johnson and Johnson, Nateera Inter..
09/21 JOHNSON & JOHNSON : J&J's vision
09/21 Indian pharma firms in global alliance to fight drug resistance
More news
Sector news : Pharmaceuticals - NEC
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
01:46p Pfizer abandons plan to split into two
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
06:57aDJPFIZER : Won't Pursue a Split
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:20a QUINTILES TRANSNATIONAL : A Total Return Growth Biopharmaceutical (Part 7 Single..
09/23 SNIPPET ROUNDUP : Firsts For Chinese CAR Companies, Setbacks For J&J And Mast
09/23 Preliminary results from mid-stage study of triple combination HCV regimen sh..
09/23 Priority Review Vouchers Revisited
09/23 10 Of 30 Follower Fave Dogs Survive Dividend Safety Check
Advertisement
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,64%
P/E ratio 2016 20,23
P/E ratio 2017 17,83
EV / Sales 2016 4,31x
EV / Sales 2017 4,03x
Capitalization 325 050 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
GLAXOSMITHKLINE PLC20.39%104 476
More Results